CODEXIS, INC.

CDXS

Explore Our Financial Data > Companies > CODEXIS, INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CDXS
CIK	0001200375
SIC	2860
Sector	Manufacturing
Industry Category	Chemicals
Industry Group	Industrial Organic Chemicals

Contact

Address	200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063
Website	codexis.com
Phone	650-421-8100
CEO	Stephen G. Dilly
Employees	250

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$52.93 million
Pre-Tax Income	$-63.92 million
Net Income	$-63.95 million
Net Income to Common	$-63.95 million
EPS	$-0.75

View All

Balance Sheet

Cash	$25.35 million
Assets	$123.96 million
Liabilities	$85.42 million
Common Equity	$38.54 million
Liabilities & Equity	$123.96 million

View All

Cash Flow Statement

Net Income	$-63.95 million
Cash From Operating Activities	$-55.94 million
Cash From Investing Activities	$14.93 million
Cash From Financing Activities	$28.88 million
Change in Cash	$-12.13 million

View All

Calculations

NOPAT	$-41.75 million
EBITDA	$-61.83 million
Price to Earnings	N/A
Price to Book	$3.82
ROE	-114.26%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer

SOUTH SAN FRANCISCO, Calif. & SEATTLE, November 17, 2025--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Board of Directors has appointed Stephen Dilly, MBBS, PhD, former President and Chief Executive Officer (CEO) of Codexis, Inc., and current Chair of the Codexis Board, as the Company’s new President, CEO and member of the Board of Directors, effecti

Article Link

Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Article Link

Codexis Announces Signing of Lease for GMP Manufacturing Facility

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The comp

Article Link

Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ...

Despite revenue declines, Codexis Inc (CDXS) focuses on innovation and strategic partnerships to drive long-term success.

Article Link

Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link